AI Analysis
Generated: 1 week ago. (Likely Outdated!)
Sopharma AD (SPH.WA) is a leading pharmaceutical company based in Bulgaria, with a significant presence across Eastern and Southeastern Europe. The company's business model is built on two main pillars: making medicines and distributing a wide range of health-related products.
The Business Model (How They Make Money)
Sopharma makes money primarily by developing, manufacturing, and selling a variety of pharmaceutical products. These include a broad range of generic medicines (which are cost-effective versions of branded drugs), herbal-based medicines, food supplements, veterinary products, medical devices, and even cosmetic products like plasters and bandages. Some of their well-known brands include Carsil, Tempalgin, Tabex, Tribestan, Broncholytin, and Analgin. The actual production of these goods mainly happens in Bulgaria through Sopharma AD itself, and in Serbia and Ukraine through its subsidiaries.
Beyond manufacturing, Sopharma also has a strong distribution network. They act as a wholesaler for pharmaceuticals, medical supplies, vitamins, and other health products. This distribution arm, largely managed by "Sopharma Trading," serves markets in Bulgaria, Serbia, Russia, Ukraine, Kazakhstan, Poland, and Belarus. The company also has smaller operations in pharmacy retail and real estate leasing.
Sopharma operates in approximately 41 countries, with key markets including Bulgaria, Russia, Ukraine, Kazakhstan, and Poland. A significant portion of their growth comes from selling products internationally; for instance, in early 2026, a 33% increase in exports was a major driver of their overall sales growth. For the period from the beginning of 2026 through the end of September, the company saw a 39% increase in total sales compared to the same period in the previous year, with export sales growing by an impressive 62%.
In 2025, Sopharma Group reported consolidated revenues of BGN 2,609,827 thousand (approximately 2.61 billion Bulgarian Leva).
The Metrics That Matter Most
For Sopharma, a company involved in both manufacturing and distributing health products across multiple countries, here are the most important numbers to watch:
- Revenue: This number tells you the total amount of money Sopharma brings in from selling its products and services. For a company like Sopharma that is focused on expanding its reach and product portfolio, consistent revenue growth shows that more people are buying their medicines and using their distribution services. In 2025, Sopharma Group's consolidated revenue was BGN 2,609,827 thousand. The company also reported strong sales growth in 2026, with a 39% increase in sales for the first nine months compared to the same period in 2025.
- EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization): Think of EBITDA as a way to see how much cash the company's core business operations are generating before accounting for things like interest payments on loans, taxes, and the cost of wear and tear on its equipment and buildings. For a company with manufacturing facilities and a wide distribution network, EBITDA helps you understand the true profitability of its day-to-day operations, without the noise of financial or accounting decisions. Sopharma Group's consolidated EBITDA for 2025 was BGN 219,181 thousand.
- Shares Outstanding: This simply tells you the total number of company shares that are currently owned by investors. It's important because many financial calculations, like earnings per share or dividends per share, are based on this number. Knowing the shares outstanding helps you understand how much of the company each share represents. As of the end of 2025, Sopharma AD had 539,157,603 shares outstanding.
- Dividends: This is the portion of the company's profits that it pays out to its shareholders. For many investors, especially those looking for regular income, dividends are a key indicator of a company's financial health and its commitment to returning value to its owners. Sopharma approved a gross dividend of EUR 0.052 per share for the year 2025.
How to Value This Company
The most relevant way to figure out if Sopharma's stock is cheap or expensive, given its business model, is by looking at its EV/EBITDA (Enterprise Value to EBITDA).
Here's why: Sopharma is a company with significant physical assets (like manufacturing plants) and a broad distribution network, which often involves debt to fund operations and expansion. EV/EBITDA helps you compare the total value of the company (its "Enterprise Value," which includes both its stock market value and its net debt) against its core operational earnings (EBITDA).
In simple terms, it tells you how many years of operational earnings it would take to "buy" the entire company, including its debt. It's a great tool for comparing Sopharma to other pharmaceutical manufacturers and distributors, especially those that might have different levels of debt or tax situations. A lower EV/EBITDA ratio might suggest the company is undervalued compared to its operational performance, while a higher ratio could mean it's considered more expensive.
鈿狅笍 Disclaimer: This analysis is generated by AI. stockpicker.tech is not responsible for any mistakes, inaccuracies, or hallucinations. This is for educational purposes only and does not constitute financial advice. Users should always double-check the information and conduct their own research before making investment decisions.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Sopharma AD
Earnings: SPH.WA
Estimate against actual revenue and earnings per share, the beat and miss record of recent reports, and how the price moved around each one. Next report: 2 Dec 2026.
Video analysis: SPH.WA
All videosNo video analysis for this stock yet. Request one from our team.
News: SPH.WA
Similar companies
-
Krka, d. d.
KRK.WA
·
Warsaw Stock Exchange
Compare
-
Neuca S.a.
NEU.WA
·
Warsaw Stock Exchange
Compare
-
Synthaverse S.A.
SVE.WA
·
Warsaw Stock Exchange
Compare
-
Celon Pharma S.A.
CLN.WA
·
Warsaw Stock Exchange
Compare
-
Bioton S.a.
BIO.WA
·
Warsaw Stock Exchange
Compare
-
Mabion S.A.
MAB.WA
·
Warsaw Stock Exchange
Compare